A Phase II Study of Toripalimab in Combination with Gemcitabine and 5-Fluorouracil as First-Line Therapy for Advanced or Metastatic Biliary Tract Carcinoma
Fangyong Lei, Wenjing Deng, Ying Zhou, Lilan Fang, Xiuxin Lin, Lingyu Qin, Chunming Li, Jian Rao, Gengsheng Yu · 2025
Read A Phase II Study of Toripalimab in Combination with Gemcitabine and 5-Fluorouracil as First-Line Therapy for Advanced or Metastatic Biliary Tract Carcinoma by Fangyong Lei, Wenjing Deng, Ying Zhou, Lilan Fang, Xiuxin Lin, Lingyu Qin, Chunming Li, Jian Rao, Gengsheng Yu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12784805.txt.
Description
Fangyong Lei and co-authors run a phase two trial of a drug trio for bile tract cancer in a 2025 study. The cancer is rare and grim once it spreads. The trio joins an immune drug, toripalimab, with two chemo drugs, gemcitabine and 5-FU. Thirty patients with spread or fixed disease took the trio as first care. Main grades were time with no growth and share of tumors that shrank. Marks that might call the gain were also probed.
Tumors shrank in 13 percent of patients. Mid spans ran 5.3 months with no growth and 11.7 months of life. Two marks, PD-L1 and mutation load, did not call who gained. All patients felt side effects; one in four hit the harsh grades, led by low blood counts. No deaths came from care. The authors call the trio sound and safe enough for big trials.
Catalog record
| CREATOR | Fangyong Lei, Wenjing Deng, Ying Zhou, Lilan Fang, Xiuxin Lin, Lingyu Qin, Chunming Li, Jian Rao, Gengsheng Yu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |